Sep, 12 2017 23:37 JST

Source: Eisai

Eisai Selected for Fifth Consecutive Year of Membership in Dow Jones Sustainability Asia Pacific Index 2017


TOKYO, Sep, 12 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for a fifth consecutive year of membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI).

The DJSI family was jointly established between RobecoSAM AG (Switzerland) and S&P Dow Jones Indices LLC (United States) in 1999 as the first global SRI indices in the world and assesses the corporate sustainability performance of eligible member companies based on economic, environmental and social criteria. This year, the DJSI Asia Pacific has selected 152 companies leading the way in sustainability (72 of which are from Japan) from among the region's top 614 companies. Eisai received high scores particularly in categories such as Codes of Business Conduct, Product Quality and Recall Management, Labor Practice Indicators as well as Strategy to Improve Access to Drugs or Products.

In addition to the DJSI Asia Pacific, Eisai has been selected for the 16th consecutive year since 2002 as a member of the FTSE4Good Index Series, another global benchmark SRI index.

The Eisai Group's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Guided by this philosophy, Eisai will continue to develop innovative new drugs and make them available to patients around the world as early as possible to fulfill its social responsibility and secure the trust of stakeholders.


About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech, HealthCare

Copyright ©2017 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai: Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25mg in Japan
October 13 2017 09:48 JST
 
Small and Easy to Take, Just One Tablet per Dose Eisai to Launch "Onji-No-Megumi" for Improving Forgetfulness in Middle Age and Beyond
October 11 2017 11:48 JST
 
Eisai and Biotoscana Sign Exclusive Licensing Agreement for Latin America
October 04 2017 09:49 JST
 
Sato Pharmaceutical and Eisai to Co-Promote New Oral Antifungal Agent Containing Active Ingredient Fosravuconazole in Japan
October 03 2017 14:11 JST
 
Eisai Presents Results of Phase Iii Trial of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma in Oral Session at 20th CSCO Annual Meeting
September 29 2017 15:12 JST
 
Eisai: Application for Additional Indication of Lenvima for Hepatocellular Carcinoma Accepted for Review by U.S. FDA
September 27 2017 12:25 JST
 
Eisai: Additional Dosage and Administration of Proton Pump Inhibitor Pariet 5 mg Tablets, 10 mg Tablets Approved in Japan for Maintenance Therapy of Proton Pump Inhibitor Resistant Reflux Esophagitis
September 22 2017 15:46 JST
 
Eisai Presents Latest Non-Clinical Data on Its First Antibody-Drug Conjugate MORAb-202 at 8th Annual World ADC
September 22 2017 09:56 JST
 
Eisai Presents Results of Phase Iii Clinical Study of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma at 11th ILCA Annual Conference
September 19 2017 09:01 JST
 
Eisai to Launch New "Etak Antimicrobial Spray Alpha" Containing Long-Acting Antimicrobial Agent Etak
September 13 2017 13:25 JST
 
More Press release >>

Latest Press Release


More Latest Release >>